Genetic manipulation of the ApoF/Stat2 locus supports an important role for type I interferon signaling in atherosclerosis

Atherosclerosis

Volumn 233, Issue 1, 2014, Pages 234-241

  Lagor, William R ^a   Fields, David W ^a   Bauer, Robert C ^a   Crawford, Alison ^b   Abt, Michael C ^b   Artis, David ^b   Wherry, E John ^b   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ApoF; Atherosclerosis; STAT2; Type I IFN

Indexed keywords

APOF; ATHEROSCLEROSIS; STAT2; TYPE I IFN;

ANIMALS; AORTA; APOLIPOPROTEINS; ATHEROSCLEROSIS; INTERFERON TYPE I; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, LDL; SIGNAL TRANSDUCTION; STAT2 TRANSCRIPTION FACTOR;

EID: 84893819244     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.043     Document Type: Article

References (29)

1. Day J.R., Albers J.J., Gilbert T.L., et al. Purification and molecular cloning of human apolipoprotein F. Biochem Biophys Res Commun 1994, 203:1146-1151.
2. Morton R.E., Gnizak H.M., Greene D.J., et al. Lipid transfer inhibitor protein (apolipoprotein F) concentration in normolipidemic and hyperlipidemic subjects. JLipid Res 2008, 49:127-135.
3. Bancells C., Canals F., Benitez S., et al. Proteomic analysis of electronegative low-density lipoprotein. JLipid Res 2010, 51:3508-3515.
4. Lagor W.R., Brown R.J., Toh S.A., et al. Overexpression of apolipoprotein F reduces HDL cholesterol levels invivo. Arterioscler Thromb Vasc Biol 2009, 29:40-46.
5. Lagor W.R., Fields D.W., Khetarpal S.A., et al. The effects of apolipoprotein F deficiency on high density lipoprotein cholesterol metabolism in mice. PloS One 2012, 7:e31616.
6. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004, 202:8-32.
7. Yeh T.C., Pellegrini S. The Janus kinase family of protein tyrosine kinases and their role in signaling. Cell Mol Life Sci 1999, 55:1523-1534.
8. Campbell I.L. Cytokine-mediated inflammation, tumorigenesis, and disease-associated JAK/STAT/SOCS signaling circuits in the CNS. Brain Res Brain Res Rev 2005, 48:166-177.
9. Silverman R.H. Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response. JVirol 2007, 81:12720-12729.
10. Park C., Li S., Cha E., et al. Immune response in Stat2 knockout mice. Immunity 2000, 13:795-804.
11. Schindler C., Plumlee C. Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol 2008, 19:311-318.
12. Kassim S.H., Li H., Vandenberghe L.H., et al. Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis. PLoS One 2010, 5:e13424.
13. Chen L.S., Wei P.C., Liu T., et al. STAT2 hypomorphic mutant mice display impaired dendritic cell development and antiviral response. JBiomed Sci 2009, 16:22.
14. Perry S.T., Buck M.D., Lada S.M., et al. STAT2 mediates innate immunity to dengue virus in the absence of STAT1 via the type I interferon receptor. PLoS Pathog 2011, 7:e1001297.
15. Ashour J., Morrison J., Laurent-Rolle M., et al. Mouse STAT2 restricts early dengue virus replication. Cell Host Microbe 2010, 8:410-421.
16. Auser's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011, 9:e1001046.
17. Olson E.N., Arnold H.H., Rigby P.W., et al. Know your neighbors: three phenotypes in null mutants of the myogenic bHLH gene MRF4. Cell 1996, 85:1-4.
18. Fiering S., Epner E., Robinson K., et al. Targeted deletion of 5'HS2 of the murine beta-globin LCR reveals that it is not essential for proper regulation of the beta-globin locus. Genes Dev 1995, 9:2203-2213.
19. Levy Z., Rachmani R., Trestman S., et al. Low-dose interferon-alpha accelerates atherosclerosis in an LDL receptor-deficient mouse model. Eur J Intern Med 2003, 14:479-483.
20. Goossens P., Gijbels M.J., Zernecke A., et al. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab 2010, 12:142-153.
21. Siegal F.P., Kadowaki N., Shodell M., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284:1835-1837.
22. Doring Y., Manthey H.D., Drechsler M., et al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation 2012, 125:1673-1683.
23. Hooks J.J., Moutsopoulos H.M., Geis S.A., et al. Immune interferon in the circulation of patients with autoimmune disease. NEngl J Med 1979, 301:5-8.
24. Hooks J.J., Jordan G.W., Cupps T., et al. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum 1982, 25:396-400.
25. Dall'era M.C., Cardarelli P.M., Preston B.T., et al. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005, 64:1692-1697.
26. Santer D.M., Yoshio T., Minota S., et al. Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. JImmunol 2009, 182:1192-1201.
27. Bennett L., Palucka A.K., Arce E., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. JExp Med 2003, 197:711-723.
28. Manzi S., Meilahn E.N., Rairie J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145:408-415.
29. Ji Y.N., An L., Zhan P., et al. Cytomegalovirus infection and coronary heart disease risk: a meta-analysis. Mol Biol Rep 2012, 39:6537-6546.